Kardigan, Inc. (KARD)
KARD Stock Price Chart
Explore Kardigan, Inc. interactive price chart. Choose custom timeframes to analyze KARD price movements and trends.
KARD Company Profile
Discover essential business fundamentals and corporate details for Kardigan, Inc. (KARD) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
18 Jun 2026
Employees
231.00
Website
http://www.kardigan.bioCEO
Tassos Gianakakos
Description
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
KARD Financial Timeline
Browse a chronological timeline of Kardigan, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 2 Sept 2026
EPS estimate is -$0.68.
Earnings released on 26 May 2026
EPS came in at -$1.43 .
KARD Stock Performance
Access detailed KARD performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
